Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thai, Q.-A.
Right arrow Articles by Muizelaar, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thai, Q.-A.
Right arrow Articles by Muizelaar, J. P.
Related Collections
Right arrow Antiplatelets
Right arrow Other Stroke Treatment - Medical
Right arrow Acute Cerebral Hemorrhage

(Stroke. 1999;30:140-147.)
© 1999 American Heart Association, Inc.


Original Contributions

Inhibition of Experimental Vasospasm in Rats With the Periadventitial Administration of Ibuprofen Using Controlled-Release Polymers

Quoc-Anh Thai, BA; Eric M. Oshiro, MD Rafael J. Tamargo, MD

From the Department of Neurosurgery, Division of Vascular Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Md.

Correspondence to Rafael J. Tamargo, MD, Department of Neurosurgery, Division of Vascular Neurosurgery, The Johns Hopkins Hospital, 600 N Wolfe St, Meyer 7-113, Baltimore, MD 21287-7713.

Background and Purpose—The chronic phase of vasospasm after an aneurysmal subarachnoid hemorrhage may be mediated in part by early leukocyte-endothelial cell interactions. Ibuprofen is an anti-inflammatory agent that inhibits expression of certain cell adhesion molecules and therefore disrupts leukocyte-endothelial cell interactions. Its systemic administration, however, has dose-limiting side effects. We evaluated the effect of the periadventitial delivery of ibuprofen using controlled-release polymers in the rat femoral artery model of chronic posthemorrhagic vasospasm.

Methods—Before the animal studies, the release pharmacokinetics of the ibuprofen-loaded ethylene–vinyl acetate polymers were determined in vitro. Subsequently, the femoral arteries (n=266) of Fischer 344 rats (n=133) were enclosed in latex pouches bilaterally. In the toxicity study (n=15 rats), the animals were randomized into 5 dose groups in which 0%-, 10%-, 20%-, 30%-, or 50%-loaded ibuprofen polymers were evaluated. In the efficacy study, the animals were randomized into 5 time groups in which 50%-loaded ibuprofan polymers were inserted at 0 (n=58 rats), 6 (n=16), 12 (n=13), 24 (n=11), or 48 hours (n=12) after blood injection into the pouch. The rats were killed 12 days after blood exposure, at the time of maximal vasospasm in this model. Vasospasm was expressed as percent lumen patency. To evaluate the effect of ibuprofen on leukocyte migration, 8 rats were randomized into 2 groups. Macrophages and granulocytes were stained by immunohistochemistry with the use of a mouse OX-41 monoclonal antibody and counted in the periadventitial space 24 hours after blood exposure.

Results—In vitro pharmacokinetics showed that the 50%-loaded ibuprofen polymer released its total drug load over a 12-day period. In the toxicity study, a nonsignificant arterial vasodilatation with ibuprofen treatment was seen at higher doses, and no deleterious effects were noted on the vessel wall histologically. In the efficacy study, ibuprofen treatment resulted in significant vasospasm inhibition when treatment was initiated at 0 hour (73.7±4.9% versus 94.5±3.3% [mean±SEM percent lumen patency]; P<0.001) and 6 hours (69.2±5.7% versus 98.0±3.9%; P=0.002) after blood exposure, but not at 12, 24, or 48 hours. Leukocyte immunohistochemistry showed that ibuprofen treatment resulted in significantly lower periadventitial macrophage and granulocyte counts of 25.0±3.9 cells per high-powered field compared with counts of 140.5±18.2 cells per high-powered field in the untreated vessels (P<0.001).

Conclusions—The periadventitial, controlled release of ibuprofen from surgically implanted polymers significantly inhibits chronic posthemorrhagic vasospasm in this model when treatment is initiated within 6 hours of blood exposure. Vasospasm inhibition with ibuprofen correlates with a significant decrease in the number of macrophages and granulocytes in the periadventitial space. This study supports the hypothesis that inflammation mediates in part the chronic phase of posthemorrhagic vasospasm and suggests a potential alternative treatment for this condition.

Editorial Comment

J. Paul Muizelaar, MD, PhD, Guest Editor

Department of Neurosurgery, University of California at Davis, Sacramento, California




This article has been cited by other articles:


Home page
StrokeHome page
K. L. Chaichana, A. P. Levy, R. Miller-Lotan, S. Shakur, and R. J. Tamargo
Haptoglobin 2-2 Genotype Determines Chronic Vasospasm After Experimental Subarachnoid Hemorrhage
Stroke, December 1, 2007; 38(12): 3266 - 3271.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C. O. Borel, A. McKee, A. Parra, M. M. Haglund, A. Solan, V. Prabhakar, H. Sheng, D. S. Warner, L. Niklason, and A. Bhardwaj
Possible Role for Vascular Cell Proliferation in Cerebral Vasospasm After Subarachnoid Hemorrhage * Editorial Comment
Stroke, February 1, 2003; 34(2): 427 - 433.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
K. Nakai, Y. Numaguchi, T. H. Foster, K. Shima, and M. Kikuchi
Endovascular Treatment Using Low-Power Ultraviolet Laser for Delayed Vasospasm in the Rabbit Carotid Artery Model
AJNR Am. J. Neuroradiol., November 1, 2002; 23(10): 1725 - 1731.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. Gabikian, R. E. Clatterbuck, C. G. Eberhart, B. M. Tyler, T. S. Tierney, and R. J. Tamargo
Prevention of Experimental Cerebral Vasospasm by Intracranial Delivery of a Nitric Oxide Donor From a Controlled-Release Polymer: Toxicity and Efficacy Studies in Rabbits and Rats
Stroke, November 1, 2002; 33(11): 2681 - 2686.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C.J.M. Frijns and L.J. Kappelle
Inflammatory Cell Adhesion Molecules in Ischemic Cerebrovascular Disease
Stroke, August 1, 2002; 33(8): 2115 - 2122.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
B. Noel, J. E. Conway, and R. J. Tamargo
Vascular Complications of Cocaine Use * Response
Stroke, July 1, 2002; 33(7): 1747 - 1748.
[Full Text] [PDF]


Home page
StrokeHome page
M. Satoh, A. D. Parent, and J. H. Zhang
Inhibitory Effect With Antisense Mitogen-Activated Protein Kinase Oligodeoxynucleotide Against Cerebral Vasospasm in Rats
Stroke, March 1, 2002; 33(3): 775 - 781.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Satoh, I. Date, M. Nakajima, K. Takahashi, K. Iseda, T. Tamiya, T. Ohmoto, Y. Ninomiya, S. Asari, and R. L. Macdonald
Inhibition of Poly(ADP-Ribose) Polymerase Attenuates Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbits Editorial Comment
Stroke, January 1, 2001; 32(1): 225 - 231.
[Abstract] [Full Text] [PDF]